We are live on ! Find out more
VVC

Vectren
VVC

Delisted

VVC was delisted on the 31st of January, 2019.

277 hedge funds and large institutions have $2.07B invested in Vectren in 2014 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 80 increasing their positions, 107 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more capital inflows, than outflows

Capital inflows: $127M | Capital outflows: $100M

26% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 19

2% more funds holding

Funds holding: 271 → 277 (+6)

0.81% more ownership

Funds ownership: 58.26% → 59.07% (+0.81%)

25% less repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 107

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
277
Holders Change
+6
Holders Change %
+2.21%
% of All Funds
7.93%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
24
Increased
80
Reduced
107
Closed
19
Calls
$272​K
Puts
–
Net Calls
+$272​K
Net Calls Change
+$19​K

VVC Hedge Fund Activity: Q2 2014 in Review

277 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Vectren (VVC) for Q2 2014, worth a combined $2.07B — up 9.4% from $1.89B a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new VVC positions and 19 closed out — a net gain of 5 holders — while 80 added to existing stakes and 107 trimmed.

The largest buyer was Axa, adding an estimated $16.8M. The largest seller was Goldman Sachs, cutting an estimated $7.7M.

  • 277 institutional investors held Vectren (VVC) as of Q2 2014, up from 271 in Q1 2014.
  • Funds reported $2.07B of Vectren stock for Q2 2014, up 9.4% quarter-over-quarter.
  • 24 funds opened new Vectren positions in Q2 2014 and 19 closed out, a net change of +5 holders.
  • The largest Vectren buyer in Q2 2014 was Axa, an estimated $16.8M added.
  • The largest Vectren seller in Q2 2014 was Goldman Sachs, an estimated $7.7M sold.

Based on aggregated 13F filings for Q2 2014.